Other languages Daiichi Sankyo Co., Ltd.

Equities

4568

JP3475350009

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-05-31 am EDT			5-day change	1st Jan Change
5,578 ^JPY	+3.32%		+2.46%	+44.06%

May. 28	RevolKa Signs Master Service Agreement with Daiichi Sankyo	CI
May. 27	AstraZeneca, Daiichi Sankyo's Experimental Lung Cancer Drug Shows Improvement in Patients	DJ

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Daiichi Sankyo - Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial	May. 28
RevolKa Signed Master Service Agreement with Daiichi Sankyo	May. 28
RevolKa Signs Master Service Agreement with Daiichi Sankyo	May. 27
AstraZeneca, Daiichi Sankyo's Experimental Lung Cancer Drug Shows Improvement in Patients	May. 27
AstraZeneca, Daiichi Sankyo’s Lung Cancer Drug Shows Mixed Results in Late-stage Trial	May. 27
AstraZeneca's Lung Cancer Drug Shows Clinically Meaningful Improvement in Overall Survival	May. 27
Astra, Daiichi hail positive survival data for Dato-DXd	May. 27
Datopotamab Deruxtecan Showed Clinically Meaningful Overall Survival Improvement Versus Chemotherapy in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial	May. 27
Daiichi Sankyo and AstraZeneca PLC Provides an update on TROPION-Lung01 Phase 3 Trial	May. 27
Jefferies Adjusts Daiichi Sankyo’s Price Target to 6,600 Yen From 5,600 Yen, Keeps at Buy	May. 24
Daiichi Sankyo Highlights Progress in Creating New Standards of Care for Patients Across Multiple Cancers at ASCO	May. 21
AstraZeneca to build $1.5-bln cancer drug plant in Singapore	May. 20
Merck : va présenter de nouvelles données en oncologie	May. 15
IHH Healthcare Unit Submits Claim Brief Against Daiichi Sankyo in Tokyo Court	May. 15
Daiichi Sankyo : Announces Appointments of Directors(251.4KB	May. 14
Japan's Nikkei closes at 3-week high on US rate-cut outlook, tech boost	May. 07
Japan's Nikkei climbs on Fed rate-cut outlook, tech boost	May. 06
Remsons, Daiichi Infotainments Form Joint Venture	Apr. 30
AstraZeneca Says Enhertu Phase 3 Trial Shows 'Statistically Significant' Progression-Free Breast Cancer Survival Improvement	Apr. 29
AstraZeneca PLC and Daiichi Sankyo Announces ENHERTU (Fam-Trastuzumab Deruxtecan-Nxki) Improved PFS in HER2-Low and Ultralow	Apr. 29

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Daiichi Sankyo Co., Ltd.

Equities

4568

JP3475350009

Other languages

Filters